Kurve Technology achieves success in Alzheimer’s study

The results could be significant for the treatment of Alzheimer’s as recent evidence suggests that disorders of insulin metabolism, such as insulin resistance and diabetes, increase the risk for developing Alzheimer’s disease. Furthermore delaying its onset by five years could reduce the number of individuals with Alzheimer’s disease by nearly 50% after 50 years.

Results of the study showed that compared to the placebo group, the insulin-treated group showed enhanced ability to retain verbal information after a delay. Although memory savings scores were no different between the two groups at baseline, they were significantly higher in the insulin-treated group at day 21.

During the six month trial, ViaNase delivered over 1,000 doses without a single failure. Treatment was well-tolerated, with no serious adverse events or changes in plasma glucose or insulin levels. A longer-term trial will begin in October.

“Intranasal insulin administration improved memory by about 20%,” said VA principal investigator Suzanne Craft. “This degree of memory improvement can be considered clinically significant.”

“In addition to improvement in daily function and memory, study participants and their caregivers found the device easy to use and extremely reliable,” said Kurve Technology’s CEO Marc Giroux.

According to the Alzheimer’s Association, an estimated 4.5 million Americans have Alzheimer’s disease